Actinium Pharmaceuticals (NYSE:ATNM) Given “Overweight” Rating at Stephens

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “overweight” rating reiterated by equities research analysts at Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. Stephens’ price target suggests a potential upside of 406.07% from the stock’s previous close.

Actinium Pharmaceuticals Price Performance

NYSE ATNM opened at $0.99 on Tuesday. The company has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.36. Actinium Pharmaceuticals has a 1 year low of $0.99 and a 1 year high of $1.95. The company has a market capitalization of $30.82 million, a PE ratio of -0.73 and a beta of -0.31.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Actinium Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after purchasing an additional 12,703 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Actinium Pharmaceuticals by 35.4% in the fourth quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock valued at $531,000 after acquiring an additional 102,154 shares in the last quarter. Two Sigma Investments LP grew its holdings in Actinium Pharmaceuticals by 403.4% during the 3rd quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after acquiring an additional 187,748 shares in the last quarter. Jane Street Group LLC acquired a new position in Actinium Pharmaceuticals in the second quarter worth about $306,000. Finally, Marshall Wace LLP acquired a new stake in Actinium Pharmaceuticals during the second quarter valued at approximately $137,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.